A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Table 2 Efficacy, cardiotoxicity and early death rate of CAG in MDS/t-AML

Study (ref)	Year	No. Patients *	Median age (range)	Aclarubicin dosage	MDS/t-AML No.	CR No.	CR %	CT No.	ED No.
Saito [38]	2000	69	51 (15-82)	10 or 14 mg/m² × 4d	18	8	44	0	0
Li [26]	2005	112	47 (15-81)	14 mg/m² × 4d or 8 mg/m² × 8d	13	5	39	0	0
Sui [56]	2008	17	NR(26-73)	10-14 mg/m² × 4d	17	6	35	0	0
Jin [57]	2008	14	NR(38-78)	10-14 mg/m² × 4d	14	6	43	0	0
Deng [58]	2008	39	NR(52-78)	5-6 mg/m²×7d	16	9	55	0	0
Su [59]	2009	33	60 (28-77)	10 mg/d × 8d	33	14	42	1	0
Ni [51]	2009	70	NR(22-85)	14 mg/m² × 4d	9	5	56	0	1
Ma [28]	2010	31	NR(19-71)	14 mg/m² × 4d	5	3	60	0	0
Li [60]	2010	20	NR(36-74)	5-7 mg/m² × 8d	20	9	45	0	0
Zhu [61]	2010	46	54 (31-72)	10 mg/m² × 8d	28	13	46	0	0
Chen [62]	2010	27	NR(21-72)	10 mg/d × 8d	27	15	56	0	0
Liang [54]	2010	54	NR(17-82)	5-7 mg/m² × 8d	15	5	33	0	2

Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MDS/tAML: MDS or MDS transformed AML; Ref: references; NR: not reported; *: total number of AML and MDS patients; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.

ISSN: 1756-8722